Urinary survivin mRNA expression and urinary nuclear matrix protein 22 BladderChek® and urine cytology in the detection of transitional cell carcinoma of the bladder

Medical Principles and Practice

Volumn 21, Issue 3, 2012, Pages 295-297

  Al Maghrebi, May ^a   Kehinde, Elijah O ^a   Kapila, Kusum ^a   Anim, Jehoram T ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

Author keywords

Bladder cancer; NMP22 BladderChek ; Real time PCR; Survivin; Urine cytology

Indexed keywords

MESSENGER RNA; NUCLEAR MATRIX PROTEIN 22; SURVIVIN;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NMP22BC TEST; PROSPECTIVE STUDY; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; TRANSITIONAL CELL BLADDER CARCINOMA; TRANSITIONAL CELL CARCINOMA; URINALYSIS; URINE CYTOLOGY;

ADOLESCENT; ADULT; AGED; ANTIGENS, NEOPLASM; CARCINOMA, TRANSITIONAL CELL; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CONFIDENCE INTERVALS; CYTODIAGNOSIS; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NUCLEAR PROTEINS; PREDICTIVE VALUE OF TESTS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 84859603556     PISSN: 10117571     EISSN: 14230151     Source Type: Journal    
DOI: 10.1159/000334811     Document Type: Article

References (9)

1. Grossman HB, Soloway M, Messing E, Katz G, Stein B, Kassabian V, Shen Y: Detection of bladder cancer using a point-of-care proteomic assay. JAMA 2005;293:810-816. (Pubitemid 40250364)
2. Budman LI, Kassouf W, Steinberg JR: Biomarkers for detection and surveillance of bladder cancer. Can Urol Assoc J 2008;2:212-221.
3. Kapila K, Kehinde EO, Anim JT, Mojiminiyi OA, Vinsu A, George SS, Al-Maghrebi M, Al-Mulla F: Could nuclear matrix protein 22 (NMP22) play a role with urine cytology in screening for bladder cancer? - experience at Kuwait University. Cytopathology 2008;19:369-374.
4. Eble JN, Sauter G, Epstein JI, Sesterhenn IA (eds): World Health Organization Classification of Tumours (6). Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, IARC Press, 2004, pp 90-91.
5. Kwon DH, Hong SJ: The clinical utility of BTA TRAK, BTA stat, NMP22 and urine cytology in the diagnosis of bladder cancer: a comparative study. Korean J Urol 2003;44:721-726.
6. Choi HS, Lee SI, Kim DJ, Jeong TY: Usefulness of the NMP22BladderChek test for screening and follow-up of bladder cancer. Korean J Urol 2010;51:88-93.
7. Xia Y, Liu Y, Yang K, Chen W: The diagnostic value of urine-based survivin mRNA test using reverse transcription polymerase chain reaction for bladder cancer: a systematic review. Chin J Cancer 2010;29:441-446.
8. McNeil BK, Getzenberg RH: Urine-based markers in bladder cancer: future prospects. BJU Int 2008;101:668-669. (Pubitemid 351270009)
9. Bott S, Chanawani M, Mostafid H: The use of the NMP22 bladdercheck test for bladder cancer to optimize investigations in a one-stop haematuria clinic. Br J Med Sci Surg Urol 2008;1:126-130.